Held by 5 specialist biotech funds
High Convergence# Signal Note: Avoro Capital Initiates $52M Position in PTCT Avoro's entry suggests confidence in PTC's pipeline depth, likely driven by near-term catalysts in rare disease programs where the firm has deep expertise.
AI analyst context — unlock full analysis
# Signal Note: Rock Springs Capital Initiates PTCT Position Rock Springs' $4.7M long position in PTC likely reflects conviction in near-term revenue inflection from Translarna (ataluren) in DMD, which gained EU approval in 2014 and is pursuing US label expansion, plus potential catalysts from the pipeline (including PTC299 in neurofibromatosis). As a concentrated healthcare specialist, Rock Springs' entry suggests either upcoming clinical readouts, reimbursement developments, or valuation-driven opportunity in what has been a volatile turnaround story.
+ 3more — see how much conviction went in
See the Full Story